Rexgenero company

Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.

Founded Date: Undisclosed
Total Funding: $18.7M
Investor Type: Company
Employee Number: Undisclosed
Investment Stage: N/A
Funding Status: Early Stage Venture
Number Of Exists: Grant
Technology: P4 Medicine
Last Funding Type: Grant
Investors Number: 2
Industry: Regenerative Medicine
Headquarters: London, England, United Kingdom
Estimated Revenue: $10M to $50M